Tang-Liu D D, Neff J, Zolezio H, Sandri R
Department of Pharmacokinetics, Allergan, Inc., Irvine, California 92715.
Pharm Res. 1988 Aug;5(8):477-81. doi: 10.1023/a:1015909106144.
The percutaneous absorption and distribution profile of hexamethylene lauramide (hexahydro-1-lauroyl-1H-azepine) were examined using a rat skin-flap model. After a topical dose to the skin flap, the drug concentrations in the vasculature at the site of drug application and in the systemic blood were monitored simultaneously. Hexamethylene lauramide penetrated the skin and reached a steady state in stratum corneum, viable epidermis, dermis, and cutaneous blood in 3 hr. Its concentration in the skin was much higher than that in the blood. Its apparent concentration in the epidermis was 19 times that in the dermis and about 3000 times that in the cutaneous blood. The percutaneous absorption of 14C-hexamethylene lauramide resulted in ascending systemic blood concentrations throughout the experimental period, whereas the cutaneous blood levels remained steady. The topically absorbed hexamethylene lauramide was quantitatively recovered in urine (85%) and feces (13%). The half-lives of urinary and fecal excretion of 14C-hexamethylene lauramide were 17 and 30 hr, respectively. Hexamethylene lauramide, when topically coadministered in an experimental formulation, enhanced the skin penetration of hydrocortisone with increased drug contents in the stratum corneum (2-fold) and with increased hydrocortisone concentrations in the cutaneous blood (3.4-fold) and the systemic blood (3.5-fold). The results indicated that the high concentration and retention of hexamethylene lauramide in stratum corneum and viable epidermis may contribute to its penetration enhancement effect in the skin. A steady state in percutaneous tissues was observed before the drug reached distribution equilibrium systemically. The systemic blood concentration of a topically applied agent therefore may not reflect its percutaneous kinetic processes before a systemic distribution equilibrium is reached.(ABSTRACT TRUNCATED AT 250 WORDS)
使用大鼠皮瓣模型研究了六亚甲基月桂酰胺(六氢-1-月桂酰-1H-氮杂环庚烷)的经皮吸收和分布情况。对皮瓣进行局部给药后,同时监测给药部位血管和全身血液中的药物浓度。六亚甲基月桂酰胺穿透皮肤,在3小时内在角质层、活表皮、真皮和皮肤血液中达到稳态。其在皮肤中的浓度远高于血液中的浓度。其在表皮中的表观浓度是真皮中的19倍,约为皮肤血液中的3000倍。在整个实验期间,14C-六亚甲基月桂酰胺的经皮吸收导致全身血液浓度上升,而皮肤血液水平保持稳定。局部吸收的六亚甲基月桂酰胺在尿液(85%)和粪便(13%)中被定量回收。14C-六亚甲基月桂酰胺的尿排泄和粪排泄半衰期分别为17小时和30小时。当在实验制剂中局部联合给药时,六亚甲基月桂酰胺可增强氢化可的松的皮肤渗透,角质层中的药物含量增加(2倍),皮肤血液(3.4倍)和全身血液(3.5倍)中的氢化可的松浓度增加。结果表明,六亚甲基月桂酰胺在角质层和活表皮中的高浓度和滞留可能有助于其在皮肤中的渗透增强作用。在药物全身达到分布平衡之前,观察到经皮组织达到了稳态。因此,局部应用药物的全身血液浓度可能无法反映其在达到全身分布平衡之前的经皮动力学过程。(摘要截断于250字)